Adenoviral vectors are widely used for in vivo gene delivery and gene therapy because of their high transduction efficiencies in a variety of tissues. 1, 2 Because of its high transduction efficiencies, adenoviral vector is useful in characterizing the functions and testing the therapeutic effects of a gene in vivo. Under most circumstances, constructing an E1-deleted adenoviral vector is quite straightforward. However, constructing an adenoviral vector that expresses a transgene that is potentially toxic to packaging cells can be extremely difficult. For example, constructing adenoviral vectors expressing the fas ligand (Fas-L) has been reported to be difficult because of the toxic effect on 293 cells. 3 Although adenoviral vectors expressing Fas-L have been constructed and proven to be effective in the treatment of established experimental tumor models, 293 cells that are resistant to Fas-L-induced apoptosis or the caspase inhibitor were used in that particular study to produce such a vector. 4 Alternatively, a stuffer DNA fragment flanked by lox P sites was placed between promoter and Fas-L cDNA to prevent transgene expression in 293 cells. Fas-L was then induced by coinfecting target cells with an adenoviral vector expressing were to remove the stuffer fragment. 5 More recently, 293 cells expressing poxvirus crm A were reported to produce and expand adenoviral vectors expressing Fas-L or Fas. 6 were low, probably because of incomplete suppression of apoptosis in producer cells, and the method can only be applied to genes whose function is inhibited by crm A. In the past 2 years, we have experienced difficult in constructing an adenoviral vector expressing the bax gene, a member of the Bcl-2 family and an apoptosis promoter, 7, 8 driven by the cytomegalovirus promoter. This problem was not solved by using 293 cells stably transfected with the antiapoptotic bcl-2 gene. Although there are no reports in the literature to document this difficulty, the lack of any literature on the subject in itself suggests that constructing an adenoviral vector expressing the bax gene is not an easy task. Moreover, the transfection of cancer cell lines with naked DNA containing the bax or p53 expression cassette has been shown to kill 70-90% of the transfected cells in the case of bax versus only 40% in the case of p53, suggesting that bax may be more toxic than p53. 9 We have previously shown that a synthetic GAL4-responsive promoter consisting of five GAL4-binding sites and a TATA box (GT) has low transcriptional activity in vitro and in vivo when placed in an adenoviral backbone. 10 Moreover, the transgene activity can be substantially induced in vitro and in vivo by administering this construct along with an adenoviral vector (Ad/PGK-GV16) expressing a GT transactivator, namely, the GAL4-VP16 fusion protein. The low basal level and the inducibility of this binary vector system led us to hypothesize that it might be used to construct adenoviral vectors expressing the proapoptotic gene bax. In fact, construction of an adenoviral vector containing GT-Bax (Ad/GTBax) is straightforward and induction of the bax gene expression by adenovirus-mediated gene cotransfer is quite effective.
We initially attempted to construct vectors in which the bax gene was driven by a CMV promoter, but failed in this after rigorous trials. The problem was not solved by using 293 cells stably transformed and overexpressing the bcl-2 gene (data not shown). We therefore constructed shuttle plasmids in which bax cDNA was driven by GT. Recombinant viral vectors were obtained after a single transfection of 293 cells with pAd/GT-Bax plus a 35-kb ClaI fragment from Ad/p53. 11 Virus from a single plaque was expanded in 293 cells and purified twice by ultracentrifugation on a cesium chloride gradient. The vector titer determined by optical obsorbency at A 260 was 3.3 × 10 2 viral particles/ml, equivalent to the other E1-deleted vectors, such as Ad/CMV-GFP and Ad/CMV-LacZ. The total yield for Ad/GT-Bax was also the same as for the other E1-deleted vectors produced in our laboratory, about 1.5 × 10 4 particles per cell. All the vectors used in this study were free of E1 + adenovirus and endotoxin. Particle:plaque ratios were between 30:1 and 100:1.
To test the induction of the bax gene in cultured mammalian cells by adenovirus-mediated gene cotransfer, human lung carcinoma cell lines H1299 and A549 were infected with Ad/GT-Bax and Ad/PGK-GV16 10 at a vector ratio of 2:1 and at a total multiplicity of infection (MOI) of 900 and 1500 particles, respectively. Cells were treated with PBS or infected either with Ad/GT-Bax plus Ad/CMV-GFP (a gift from Dr TJ Liu at our institution), 12 or with Ad/GT-LacZ 10 plus Ad/PGK-GV16 at the same vector ratio, and MOIs were used as controls. Cells were harvested 24 h after the treatment and their lysates subjected to Western blot analysis. Although background levels of the bax protein expression differed between H1299 and A549 cells and although the treatment with control vectors did not increase those background levels, a strong induction of bax expression was detected in both cell lines when they were treated with Ad/GT-Bax plus Ad/PGK-GV16 (Figure 1 ). The induction was observed to be 67.2-and 8.7-fold in H1299 and A549 cells, respectively, when the densities of the bax-specific bands were quantified and normalized to the density of ␤-actin bands.
Overexpression of the bax gene has been demonstrated to induce the release of Cyt c from mitochondria, which leads first to cleavage of caspase-3/CPP32 followed by cleavage of poly (ADP ribose)polymerase (PARP). 13 To test whether the induction of bax expression by adeno-
Figure 3 In vivo induction of bax gene expression. The data represent similar results from two separate in vivo experiments with five mice per group. (A) Western blot analysis of bax protein expression in livers from Balb/c mice treated with PBS (lanes 1 and 2), Ad/GT-Bax + Ad/CMV-GFP (lanes 3 and 4), Ad/GT-Bax + Ad/PGK-GV16 (lanes 5 and 6), and Ad/GT-LacZ + Ad/CMV-GV16 (lanes 7 and 8). The bax: ␤-actin ratio for each sample is listed under each lane. Each ratio is expressed in terms relative to the ratio in PBS-treated mice, which was arbitrarily set at 1. (B) Nuclear fragmentation detected by hematoxylin and eosin staining of liver sections from mice treated with (a) PBS, (b) Ad/GT-Bax + Ad/CMV-GFP, (c) Ad/GT-Bax + Ad/PGK-GV16, and (d) Ad/GT-LacZ + Ad/CMV-GV16.

Figure 3 Continued.
Gene Therapy virus-mediated gene codelivery would similarly trigger apoptosis in H1299 and A549 cells, samples of the same cell lysate from the above-mentioned experiments were subjected to Western blot analysis of the cleavage of caspase-3 and PARP. The cleavage of caspase-3 into a 17-kDa fragment and PARP into a 85-kDa fragment was detected in cells treated with Ad/GT-Bax plus Ad/PGK-GV16 but not in cells from any other experimental groups (Figure 2a) . To document the apoptosis in these cells further, H1299 and A549 cells were treated with various vectors at a total MOI of 900 and 1500 particles, respectively, as mentioned above, and observed for cytopathology and morphology changes at 48 h after treatment. Over 80% of the cells treated with Ad/GT-Bax plus Ad/PGK-GV16 showed signs of cytopathology, and became rounded and detached, whereas the cells in all other treated groups remained in monolayers with normal morphology. Nuclear fragmentation, a hallmark of cell apoptosis, was detected only in cells treated with Ad/GT-Bax plus Ad/PGK-GV16 (Figure 2b ), suggesting that bax expression by this system activated not only the caspase cascade, but ultimately extensive apoptosis in these human lung cancer cell lines.
To test whether bax gene expression could be similarly induced by adenovirus-mediated gene codelivery in vivo, adult Balb/c mice were infused via their tail veins with PBS, Ad/GT-Bax plus Ad/CMV-GFP, Ad/GT-Bax plus Ad/PGK-GV16, or Ad/GT-LacZ plus Ad/PGK-GV16 at a total vector dose of 6 × 10 10 particles per mouse and a vector ratio of 2:1. Mice were then killed at 24 h after treatment, and liver samples were harvested for Western blot analysis and histopathological examination. Western blot analysis showed a 14-fold increase in bax protein levels in animals treated with Ad/GT-Bax plus Ad/PGK-GV16, but only background level in all other treatment groups (Figure 3a) . These results clearly demonstrated that the Ad/GT-Bax plus Ad/PGK-GV16 strictly regulated bax expression by expressing GAL4/VP16 protein even in vivo. Expression of the bax gene also induced typical apoptosis in normal liver cells, as revealed by nuclear fragmentation and condensation in hematoxylin-and eosin-stained liver sections (Figure 3b ). Of note, administration of high-dose E1-deleted adenoviral vector itself will cause histopathological changes in hepatocytes, including ballooning, degeneration and apoptosis (1-3% of hepatocytes) that usually occur 2-3 days after the treatment and are followed by lymphocytic infiltration. 14, 15 However, examination of the above liver sections showed that apoptosis accounted for over 60% of hepatocytes in the animals treated with Ad/GT-Bax plus Ad/PGK- GV16 but only less than 1% of hepatocytes in all the other controls. The massive apoptosis of hepatocytes within 24 h after vector administration that was observed in all animals of the bax-expressing group but in none of the other controls indicated that it was mediated by bax overexpression. Together, these results demonstrated that adenovirus-mediated gene cotransfer could produce sufficient bax expression and induce apoptosis in vivo.
In a separate study, we have addressed the question of transduction efficiency and the optimal ratio of the two vectors in the binary adenoviral vector system. It is possible that the transduction efficiency may be reduced in the binary system because only the cells dually transduced with both vectors will express the desired transgene. To determine transduction efficiency and the optimal ratio of two vectors, H1299 cells were infected with Ad/GT-LacZ, Ad/CMV-LacZ, Ad/PGK-GV16 and Ad/GT-LacZ plus Ad/PGK-GV16 at a ratio of 10:1, 5:1, 2:1 and 1:1. A total MOI of 10 (p.f.u.) was used in each treatment. The cells were fixed 24 h after the infection and the transduction efficiency was determined by X-gal staining (Figure 4) . No blue cells were detected in cells infected with either Ad/PGK-GV16 or Ad/GT-LacZ. Transduction efficiency as determined by the percentage of blue areas with the Optimas software were not significantly different among cells treated with Ad/CMV-LacZ, Ad/GT-LacZ plus Ad/PGK-GV16 at the ratio of 2:1 and 1:1 (P у 0.24). Transduction efficiencies were, however, lower in groups treated with Ad/GT-LacZ plus Ad/PGK-GV16 at the ratio of 10:1 and 5:1 (P р 0.033). These results suggest that transduction efficiency is not hampered in the binary vector system at the optimal ratio of two vectors. It is likely that, even in the case of Ad/CMV-LacZ, more than one copy of vector genome per cell will be required to produce a visible blue color by X-gal staining.
In conclusion, our successful induction of bax gene expression and of apoptosis in target cells by using a GAL4 gene regulatory system and adenovirus-mediated gene cotransfer suggests that it may provide an alternative approach to constructing adenoviral vectors expressing proapoptotic and/or cytotoxic genes. The fact that the transduction efficiency was not hampered by using two vectors suggested that the vector dose may not be increased in the binary vector system in order to achieve a similar therapeutic effect as that of a single vector system. Our results also suggest that overexpression of the bax gene may cause toxic side-effects, as massive hepatocyte apoptosis was observed after intravenous infusion of the bax expressing vectors. However, because the expression of the bax gene is fully dependent on the presence of the GAL4/VP16 fusion protein, it may be that the expression of a proapoptotic gene targeted to certain target cells can be achieved by using a tissue-or cell-type specific promoter to drive the GAL4/VP16 fusion protein. Nevertheless, since PGK is a ubiquitous promoter, induction of bax gene expression by Ad/PGK-GV16 should be useful for testing therapeutic values of the gene in a variety of cancer cells.
